活血化瘀复方制剂醒脑偏瘫胶囊治疗缺血性脑卒中急性期的临床研究(1)
 |
| 第1页 |
参见附件(1942KB，2页)。
[摘要] 目的：评价活血化瘀复方制剂醒脑偏瘫胶囊治疗缺血性脑卒中急性期的临床疗效和安全性。方法：将100例急性缺血性脑卒中患者按随机原则分为治疗组(50例)和对照组(50例)。两组均治疗15 d。结果：醒脑偏瘫治疗组与对照组比较，三酰甘油、纤维蛋白原明显降低，脑梗死患者临床症状显著改善，神经功能缺损程度评分明显降低。治疗组的总有效率(94%)明显优于对照组(86%)。肝肾功能未出现异常。结论：醒脑偏瘫胶囊能显著降低神经功能缺损程度，改善脑梗死患者临床症状，降低三酰甘油、纤维蛋白原，治疗急性缺血脑卒中安全有效。
[关键词] 活血化瘀复方制剂；醒脑偏瘫胶囊；缺血性脑卒中；临床研究
[中图分类号] R255.2 [文献标识码]B [文章编号]1674-4721(2011)05(c)-093-02
Clinical research compound preparation of promoting blood circulation to remove blood stasis -Xingnaopiantan capsule on ischemia apoplexy at acute stage
WANG Zhiping
Liuyang Hospital of Tradinational Chinese Medcine, Hunan Province, Liuyang 410300, China
[Abstract] Objective: To observe the effects of xingnaopiantan capsule on the ischemia apoplexy cases at acute stage. Methods: 100 ischemia apoplexy cases were randomly divided into treatment group (treatedwith xingnaopiantan capsule)(n=50) and control group (n=50). The two groups were continuously treated for 15 days. Results: Compared with control group, the level of triglyceride and, fibrinogen was obviously decreased in the treatment group, the clinical symptoms of cerebral infarction patients were significantly improved, and the neurological function deficit scores were obviously decreased in the treatment group. The total effective rate of the treatment group (94%) obviously surpassed the control group (86%). The liver and kidney function were all normal. Conclusion: The xingnaopiantan capsule is effective and safe on ischemia apoplexy by improving the degree of neurologic impairment and the clinical symptoms of cerebral infarction patients, decreasing the level of triglyceride and fibrinogen too.
[Key words] Compound preparation of promoting blood circulation to remove blood stasis; Xingnaopiantan capsule; Ischemia apoplexy; Clinical research
脑卒中的发病率、致残率和病死率相当高，缺血性脑卒中占大多数，越来越多的学者认为使用中药制剂与西药联合治疗缺血性脑卒中，比单纯西药治疗能取得更好的治疗效果和预后。笔者通过临床观察，探讨湖南省浏阳市中医院自制活血化瘀复方制剂醒脑偏瘫胶囊治疗缺血性脑卒中急性期的临床疗效及安全性，现总结如下：
1资料与方法
1.1一般资料
收集湖南省浏阳市中医院神经内科2008年1月~2010年1月住院治疗的脑梗死患者100例，按照随机数字表分为治疗组和常规治疗对照组，每组50例。
1.1.1诊断标准西医：参照1995年中华医学会第四次脑血管疾病学术会议制定的诊断标准[1]。中医：参照国家中医药管理局全国中医脑病急症科研协作组制定的《脑卒中病诊断疗效评定标准》(1995年)[2]。 ......
您现在查看是摘要介绍页，详见PDF附件(1942KB，2页)。